Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Sep 21, 2016The Light of Life Foundation, ThyCa: Thyroid Cancer Survivors' Association, and Eisai Team Up to Increase Awareness by Urging People with Thyroid Cancer to Share their Experiences
A thyroid cancer diagnosis can lead to significant distress as patients and caregivers cope with various medical, emotional and economic challenges, as survivors, patients and caregivers have...
-
Sep 21, 2016
Eisai Inc. announced today the presentation of abstracts at the 86th Annual Meeting of the American Thyroid Association (ATA) that highlight an investigational Phase 2 trial currently recruiting...
-
Jun 2, 2016Combination treatment recently approved by FDA for Patients with Advanced Renal Cell Carcinoma Following Prior Anti-angiogenic Therapy
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Novartis Pharmaceuticals Corporation, an affiliate of Basel, Switzerland-based Novartis AG, have entered into an agreement to...
-
May 24, 2016- Abstracts include sub-analysis from second pivotal trial of Halaven® to show overall survival advantage, which supported January FDA approval in advanced liposarcoma
Eisai Inc. announced today presentations of new analyses of studies supporting U.S. Food and Drug Administration (FDA) approvals at the 2016 American Society of Clinical Oncology (ASCO) Annual...
-
May 13, 2016- Near-tripling in progression-free survival demonstrated by LENVIMA and everolimus when compared with a standard of care advances treatment paradigm in this category
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved LENVIMA® (lenvatinib), the company's multiple receptor tyrosine kinase inhibitor, in combination with...
